Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Timo Manz
Observed name:
Manz, Timo
Institutions:
Universitätsklinikum Tübingen,
Immatics Biotechnologies (Germany),
University of Tübingen
Observed institutions:
German Cancer Research Center,
Universitätsklinikum Tübingen,
University Children's Hospital Tübingen,
Immatics Biotechnologies (Germany),
Deutsches Konsortium für Translationale Krebsforschung,
University of Tübingen
show all 6
ORCID:
0000-0003-0062-2902
Observed ORCID:
0000-0003-0062-2902
OpenAlex ID:
A5076142198
An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers
2023
·
Latifa Zekri
, Martina Lutz
, et al.
·
Molecular Therapy
·
58
An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer
2020
·
Latifa Zekri
, Fabian Vogt
, et al.
·
EMBO Molecular Medicine
·
57
PDF
B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma
2022
·
Ilona Hagelstein
, Monika Engel
, et al.
·
Frontiers in Immunology
·
20
Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro
2023
·
Latifa Zekri
, Natalia Ruetalo
, et al.
·
Frontiers in Immunology
·
6
PDF
Abstract 2865: CC-3, an IgG-based B7-H3xCD3 bispecific antibody for targeting of gastrointestinal cancers
2022
·
Latifa Zekri
, Martina S. Lutz
, et al.
·
Cancer Research
·
2
Abstract A131: Targeting B7-H3 (CD276) in neuroblastoma: In vitro evaluation of Fc-optimized antibodies and immunocytokines
2019
·
Florian Heubach
, Patrick Schlegel
, et al.
·
Cancer Immunology Research
·
2
Abstract 3797: Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of CD3-bispecifics and mitigate T cell exhaustion
2025
·
Latifa Zekri
, Nisha Prakash
, et al.
·
Cancer Research
·
1
369 Tumor-restricted checkpoint inhibition by bispecific PD-1 antibodies targeting endoglin and B7-H3
2026
·
Martina S Lutz
, Kevin Wang
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Generation of a highly versatile TCR bispecific scaffold optimized for targeting tumor-specific peptide-HLA antigens
2026
·
Martin Hofmann
, Felix Unverdorben
, et al.
·
mAbs
PDF
Bivalent bispecific CD28-antibodies reinforce T-cell responsiveness and revert anergy/quiescence in patients treated with bispecific CD3-antibodies
2026
·
Latifa Zekri
, Natalie Köhler
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
PDF
1298 Two targets, two signals: combinatorial cancer therapy with bispecific antibodies directed to CD3 and CD28 improves specificity and prevents T-cell exhaustion
2024
·
Ilona Hagelstein
, Latifa Zekri
, et al.
·
Journal for ImmunoTherapy of Cancer
Show more works
View as search
Works count:
12
Citation count:
146
H-index:
4
I10-index:
3
Year
Topic
Type